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Objective Bipolar disorder (BD) is frequently misdiagnosed as major depressive disorder (MDD), which may lead to inappropriate treat-
ment and poor outcomes. This study aimed to examine prescribing patterns of antidepressants, antipsychotics and mood stabilizers in BD
patients misdiagnosed with MDD in China.
Methods A total of 1487 patients originally diagnosed with MDD were consecutively screened for diagnostic revision in 13 psychiatric
hospitals or psychiatric units of general hospitals in China nationwide. The patients’ sociodemographic and clinical characteristics were
recorded using a standardized protocol and data collection procedure. The Mini International Neuropsychiatric Interview (MINI) was used
to establish DSM-IV diagnoses. Data on psychotropic prescriptions were collected by a review of medical records.
Results Three hundred and nine of the 1487 patients (20.8%) fulfilled DSM-IV criteria for BD; 118 (7.9%) for BD-I and 191 (12.8%) for
BD-II on the MINI. Of the BD patients (n= 309), 227 (73.5%) received any use of antidepressants, 73 (23.6%) antipsychotics and 33 (10.7%)
mood stabilizers. In multiple logistic regression analyses, compared with those with MDD, patients with BD-I were more likely to receive
antidepressants (OR 1.7, 95% CI 1.1–2.8, p= 0.02), antipsychotics (OR 1.6, 95% CI 1.04–2.5, p= 0.04) and mood stabilizers (OR 3.9,
95% CI 2.1–7.2, p< 0.001), whereas patients with BD-II were more likely to receive mood stabilizers (OR 2.4, 95% CI 1.3–4.4,
p= 0.003). There was no difference in the use of antidepressants (OR 1.1, 95% CI 0.8–1.5, p= 0.7) and antipsychotics (OR 1.3, 95%
CI 0.9–1.9, p= 0.2) between BD-II and MDD. In addition, there was no difference between BD-I and BD-II in any use of antidepressants,
antipsychotics and mood stabilizers.
Conclusions The prescription of antidepressants for BD patients misdiagnosed with MDD is very common, and only a very small proportion
of patients received guideline-concordant treatment. Considering the potentially hazardous effects of inappropriate pharmacotherapy in
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this population, continuing education and training addressing the correct diagnosis of BD and rational use of psychotropic medications are
needed in China. Copyright © 2012 John Wiley & Sons, Ltd.
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INTRODUCTION
Bipolar disorder (BD) is associated with significant
role impairment, high mortality and massive economic
burden. Although attention has focused more on mania
and hypomania in the past, recent studies suggest that
bipolar depression is closely associated with occupa-
tional impairment and risk of suicide, which leads to
severe morbidity (Valtonen et al., 2008; Rosa et al.,
2010). In addition, BD patients experience longer time
in the depressive phase compared with their manic
phase (Kupka et al., 2007). Therefore, it is vitally
important to optimize the treatment for bipolar depres-
sion (Kilbourne et al., 2005).
A depressive episode is often the first mood syndrome
at the onset of BD (APA, 2002; Solomon et al., 2006;
Angst et al., 2011), and depressive episodes occur
more frequently than hypomanic or manic phases
(APA, 2002; Solomon et al., 2006). Patients with BD,
particularly BD-II, are frequently misdiagnosed with
major depressive disorder (MDD) and may receive
inadequate or inappropriate treatment (APA, 2002;
Hirschfeld et al., 2003). Notably, antidepressant mono-
therapy is not recommended for patients with bipolar I
disorder as it can induce rapid cycling (Nivoli et al.,
2011). As a consequence, such patients may have poorer
outcome and a course of illness characterized by chronic
and recurrent mood episodes, more severe symptoms
and more impaired psychosocial functioning than those
optimally treated (Solomon et al., 2006).
Identifying the treatment patterns for this patient
population could facilitate early recognition of bipolar
depression and correction of the inappropriate treat-
ment. Yet, we could locate only one large-scale study
that described the prescribing patterns of psychotropic
medications in patients with bipolar depression mis-
diagnosed as MDD (Matza et al., 2005). Matza et al.
(2005) retrospectively compared BD patients misdiag-
nosed with MDD with recognized BD, MDD and
healthy controls. The misdiagnosed group had higher
rates of psychotic disorders than the MDD group,
whereas the prescription of antidepressants was similar
between these two groups.
The aim of this study was to examine prescribing
patterns of psychotropic medications including anti-
depressants, antipsychotics and mood stabilizers in
BD patients misdiagnosed with MDD in Chinese
clinical settings.
METHODS
Study participants and settings
This study is part of the Diagnostic Assessment Service
for People with Bipolar Disorders in China (DASP),
an ongoing nationwide study initiated by the Chinese
Society of Psychiatry that aims to develop and test the
usefulness of screening tools for BD in patients misdiag-
nosed with MDD. The first survey of the DASP project
was carried out in 13major psychiatric hospitals/units lo-
cated in the north, south, east, west and central parts of
China representing a range of clinical settings. The study
lasted from 1 September 2010 to 28 February 2011. Both
inpatients and outpatients were enrolled if they were
aged between 16 and 65 years, had a diagnosis of
DSM-IV or ICD-10 MDD based on a review of medical
records, understood the aims of the study and provided
informed consent. Exclusion criteria included (1) past
diagnosis of BD; (2) history or ongoing significant med-
ical or neurological condition(s); (3) depressive disorders
secondary to a general medical or neurological condi-
tion; and (4) electroconvulsive therapy in the past month.
The study protocol was approved by the clinical
research ethics committees of the respective study
centers. Written consent was obtained from patients or
their guardians for those who were younger than 18 years
of age as long as they verbally agreed to participate.
Instrument and assessment procedures
Patients with MDD who were receiving treatment in the
participating hospitals/units were consecutively referred
by their treating psychiatrists to the research team.
Patients fulfilling study entry criteria and providing
written informed consent were invited to complete a
clinical assessment. Demographics and clinical informa-
tion and prescription of antidepressants, antipsychotics
and mood stabilizers were collected by a review of
medical records. In this study, psychotropic drugs were
categorized according to the World Health Organization
Anatomic Therapeutic Chemical system (WHO
Collaborating Centre for Drug Statistic Methodology,
2002; Chong et al., 2010), and mood stabilizers include
valproate, lithium, carbamazepine, phenobarbital, phe-
nytoin, lamotrigine, topiramate and zonisamide. In addi-
tion, polypharmacy was defined as the concurrent use of
two or more psychotropic drugs, including antidepres-
sant, antipsychotic or mood stabilizer.
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The diagnostic assessment of BD was conducted
with the validated Chinese version of the Mini Interna-
tional Neuropsychiatric Interview (MINI), version 5.0,
to establish DSM-IV BD-I/BD-II diagnoses (Sheehan
et al., 1998; Si et al., 2009). Prior to the study, all
13 raters were trained in the use of MINI, diagnosing
BD in 20 patients with MDD. In this reliability
exercise, their judgments of BD were compared with
the best estimate diagnoses (Leckman et al., 1982);
the kappa values for each rater were more than 0.85.
Statistical analysis
Data were analyzed with the SPSS 13.0 (SPSS Inc,
Chicago, IL, USA). Descriptive statistics were used
to characterize the patients’ sociodemographic and
clinical features. Comparisons of the demographic and
clinical characteristics and use of psychotropic drugs
of patients with BD-I, BD-II and those with MDD were
performed by one-way ANOVA or chi-square test, as
appropriate. If these tests were significant, post hoc tests
were carried out. Multiple logistic regression analyses
with the “Enter” method were used to identify indepen-
dent associations of diagnoses with prescribing
patterns. In the stepwise regression analyses, any use
of antidepressants, antipsychotics, mood stabilizers and
polypharmacy were entered as the dependent variable
separately, and diagnoses (BD-I, BD-II and MDD)
based on the MINI and demographic variables that
showed significant difference between the three groups
in univariate analyses (age, sex and marital status)
were entered as independent variables. The level of
significance was set at 0.05 (two-tailed).
RESULTS
Altogether, 1757 patients were invited to participate in
this study; 270 (15.4%) refused. There was no signifi-
cant difference between the enrolled patients and
patients who did not participate in terms of age or sex.
Eventually, 1487 patients were included in the analyses.
Of the 1487 patients, 309 (20.8%) fulfilled DSM-IV
criteria for BD; 118 (7.9%) for BD-I and 191 (12.8%)
for BD-II on the basis of the MINI. Table 1 shows the
basic demographic and clinical characteristics and the
use of psychotropic drugs for the whole sample and
separately by diagnoses.
In multiple logistic regression analyses, compared
with those with MDD, patients with BD-I were more
likely to receive antidepressants (OR 1.7, 95% CI
1.1–2.8, p = 0.02), antipsychotics (OR 1.6, 95% CI
1.04–2.5, p = 0.04) and mood stabilizers (OR 3.9,
95% CI 2.1–7.2, p< 0.001), whereas patients with
BD-II were more likely to receive mood stabilizers
(OR 2.4, 95% CI 1.3–4.4, p= 0.003). There was no
difference in the use of polypharmacy between BD-I
and MDD (OR 0.98, 95% CI 0.7–1.4, p= 0.9), and no
difference in the use of antidepressants (OR 1.1, 95%
CI 0.8–1.5, p= 0.7), antipsychotics (OR 1.3, 95% CI
0.9–1.9, p= 0.2) and polypharmacy (OR 1.1, 95% CI
0.8–1.5, p= 0.7) between BD-II and MDD.
We also conducted secondary analyses comparing
prescribing patterns between BD-I and BD-II after con-
trolling for age, sex and marital status by multiple logis-
tic regression analyses. Finally, there was no significant
difference in the use of antidepressants (OR 1.7, 95%
CI 0.97–2.9, p = 0.06), antipsychotics (OR 1.2,
95% CI 0.7–2.1, p= 0.5), mood stabilizers (OR 1.6,
95% CI 0.8–3.4, p= 0.2) and polypharmacy (OR
0.9, 95% CI 0.6–1.4, p= 0.6) between the two groups.
DISCUSSION
To the best of our knowledge, this was the first nation-
wide study in China that examined the prescription
patterns of psychotropic medications in BD patients
misdiagnosed with MDD. The major finding of this
study was that antidepressants were the most com-
monly used psychotropic drugs in this population
(78.8% in BD-I and 70.2% in BD-II) followed by
antipsychotics (26.3% in BD-I and 22.0% in BD-ii),
whereas mood stabilizers were less likely to be used
(13.6% in BD-I and 8.9% in BD-II).
Antidepressants have been the mainstay of treatment
for depressive episodes of any kind. Approximately half
of patients with bipolar depression are on antidepres-
sants in daily clinical practice in the USA (Baldessarini
et al., 2007). The frequency of antidepressants used in
BD patients in this study (73.5%) was considerably
higher than the previous reported figure (50%;
Baldessarini et al., 2007), which could be explained
by the misdiagnosed BD as MDD. Our figure is also
higher than an earlier one (38.7%; Matza et al.,
2005), which is perhaps due to the difference in the
method of the surveys (cross-sectional versus retro-
spective). Multivariate analyses revealed that BD-I
patients were even more likely to receive antidepres-
sants than those with verified MDD. Earlier studies
(Kemp et al., 2008; Tafalla et al., 2009) suggested
that the clinical presentations of depression in BD
were different from that of MDD probably because
of a higher degree of brain disturbances existing in
BD than in unipolar depression (Rybakowski and
Twardowska, 1999; Borkowska and Rybakowski,
2001), which could account for the frequent lifetime
depressive episodes and the more frequent use of
antidepressants in BD than in MDD in this study.
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We found that 47.5% of the BD-I patients and
45.5% of the BD-II patients received antidepressant
monotherapy—a prescription that is not recommended
by treatment guidelines (Nivoli et al., 2011), as it can
induce either mood instability or even rapid cycling.
It is noteworthy that although some studies have found
that certain antidepressants, particularly SSRIs, are
effective and safe as a concurrent treatment for bipolar
depression (Gijsman et al., 2004), this issue remains
controversial. For example, recent studies (Baldassano
et al., 2011; Amit and Weizman, 2012) reported that
antidepressants do not have a robust effect in bipolar
depression regardless of the class of the drug or bipolar
types. In addition, some studies found that antidepres-
sants may not significantly increase the risk of switch
to manic or hypomanic episodes, particularly with
concurrent use of mood stabilizers (Baldassano et al.,
2011; Amit and Weizman, 2012). Other reports,
however, suggest that the likelihood of polarity
changes, mixed symptoms and shorter euthymic peri-
ods increase if patients are exposed to antidepressants
for longer than a year (Strejilevich et al., 2011). Given
the limited advantage and the risk of switch to mania,
it seems that antidepressants may not be useful as the
first line treatment for bipolar depression (Baldassano
et al., 2011).
Multiple logistical regression analysis revealed that
BD-I patients were more likely to receive antipsy-
chotic treatment than those with verified MDD, which
could be explained by the more frequent psychotic
symptoms associated with BD-I than MDD in this
study. Earlier studies found that the frequency of
BD patients on antipsychotic medications range
between 55% and 100%, with the pooled estimate of
68% (Tohen and Zarate, 1998). In this study, only a
small proportion of BD patients (23.6%) received













N % N % N % N % X2 df p p p p
Male 533 35.8 51 43.2 97 50.8 385 32.7 26.5 2 <0.001 0.2 0.02 <0.001
Married/cohabitating 1016 68.3 76 64.4 116 60.7 824 69.9 7.4 3 0.03 0.5 0.2 0.01
Education 5.5 6 0.5 — — —
Primary and junior secondary school 439 29.5 31 26.3 52 27.2 356 30.2
Senior secondary school 388 26.1 32 27.1 44 23.0 312 26.5
College and university 597 40.1 47 39.8 85 44.5 465 39.5
Postgraduate 63 4.2 8 6.8 10 5.2 45 3.8
Depressive episodes with psychotic symptoms 258 17.4 45 38.1 55 28.8 158 13.4 65.7 2 <0.001 0.1 <0.001 <0.001
Any use of antidepressants 1047 70.4 93 78.8 134 70.2 820 69.6 4.4 2 0.1 — — —
Paroxetine 245 16.5 25 21.2 26 13.6 194 16.5
Venlafaxine 238 16.0 18 15.3 26 13.6 194 16.5
Fluoxetine 147 9.9 14 11.9 20 10.5 113 9.6
Any use of antipsychotics 299 20.1 31 26.3 42 22.0 226 19.2 3.8 2 0.1 — — —
Quetiapine 151 10.2 17 14.4 15 7.9 119 10.1
Olanzapine 102 6.9 10 8.5 19 9.9 73 6.2
Risperidone 16 1.1 2 1.7 1 0.5 13 1.1
Any use of mood stabilizers 77 5.2 16 13.6 17 8.9 44 3.7 27.3 2 <0.001 0.2 <0.001 0.001
Valproate 48 3.2 14 11.9 8 4.2 26 2.2
Lithium 26 1.7 2 1.7 6 3.1 18 1.5
Mood stabilizer–antidepressant combination 62 4.2 12 10.2 12 6.3 38 3.2 15.4 2 <0.001 0.2 <0.001 0.04
Polypharmacya 709 47.7 56 47.5 94 49.2 559 47.5 0.2 2 0.9 — — —
Antidepressants only 735 49.4 56 47.5 87 45.5 592 50.3 1.7 2 0.4 — — —
Antipsychotics only 33 2.2 4 3.4 5 2.6 24 2.0 1.1 2 0.6 — — —
Mood stabilizers only b 10 0.7 2 1.7 5 2.6 3 0.3 — — — — — —
FDA-approved drugs for bipolar depression
OFC 26 1.7 3 2.5 5 2.6 18 1.5
Quetiapine only 14 0.9 2 1.7 3 1.6 9 0.8
Mean SD Mean SD Mean SD Mean SD F df p p p p
Age (years) 39.5 12.8 35.5 11.1 35.5 12.7 40.5 12.8 19.1 2, 1484 <0.001 0.9 <0.001 <0.001
Age at onset (years) 33.4 12.4 28.0 10.5 28.8 10.9 34.6 12.5 31.4 2, 1484 <0.001 0.6 <0.001 <0.001
Lifetime depressive episodes 2.1 2.8 3.9 4.1 2.5 3.0 1.9 2.6 31.2 2, 1484 <0.001 <0.001 <0.001 0.006
A=BD-I versus BD-II; B =BD-I versus MDD; C=BD-II versus MDD; OFC= olanzapine–fluoxetine combination.
aPolypharmacy was defined as the concurrent use of two or more psychotropic drugs, including antidepressant, antipsychotic or mood stabilizer.
bUse of mood stabilizers between the three groups was not compared because of the low frequency.
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antipsychotic drugs, which is probably due to the mis-
diagnosis of BD as MDD. Although more frequent
prescription of antipsychotics is closely associated
with manic presentation (Soares et al., 1999; Levine
et al., 2001), the unrecognized mania in the present
sample could decrease antipsychotic prescription.
In the past decades, the US Food and Drug Adminis-
tration (FDA) approved only two drugs for the treatment
of bipolar depression: the olanzapine–fluoxetine combi-
nation (OFC) and quetiapine (Baldassano et al., 2011).
Contrary to the FDA’s recommendation, in this study
only 2.5% of BD-I patients and 2.6% BD-II patients
were on OFC, whereas the corresponding figures for
quetiapine were 14.4% and 7.9%, respectively.
Most current guidelines and expert consensus state-
ments recommend mood stabilizers in the acute and
maintenance phase of BD (Goodwin, 2003). However,
only 13.6% of BD-I patients and 8.9% of BD-II
patients received them in this study although they are
both higher than the figure in MDD (3.7%). The misdi-
agnosis of BD is likely to be responsible for the low
rate of mood stabilizer prescriptions. On the other
hand, 10.2% and 6.3% of BD-I and BD-II patients,
respectively, received a combination of mood stabili-
zers and antidepressants. It should be kept in mind that
mood stabilizer–antidepressant combinations are not
proven to be superior to mood stabilizers as sole treat-
ment for bipolar depression (Nemeroff et al., 2001).
A host of studies (Bowden, 2001; Mitchell et al.,
2001; Benazzi, 2003; Rybakowski et al., 2005; Kemp
et al., 2008; Tafalla et al., 2009) suggested that there
was a difference in the clinical presentations of
depression between BD-I and BD-II. Therefore, it
was expected that the prescription patterns of poly-
pharmacy, antidepressants, antipsychotics and mood
stabilizers between the two groups would be differ-
ent. In this study, however, the results did not support
this assumption.
The major merits of this study are its large sample
and the multicentre assessment of bipolar depression
in Chinese patients treated for MDD. Limitations of
this study include, first, some important factors likely
to influence psychotropic drug prescriptions, such as
treatment settings (inpatient or outpatient), number of
episodes in the past year, prior use of medications,
response to treatment, contraindications to certain
psychotropic drugs and reimbursement policies, that
were not evaluated or recorded. Second, because of
the cross-sectional nature of the study, the causality
of the relationship between sociodemographic and
clinical factors and prescription patterns could not be
determined. Third, no standardized instruments were
used to measure the severity of depressive symptoms.
Finally, the sampling was not random, which is likely
to have an effect on the generalization of the findings.
In conclusion, the results indicate that the prescrip-
tion of antidepressants for BD misdiagnosed as MDD
is very common. Only a very small proportion of
patients received FDA-approved treatment. Consider-
ing the potentially hazardous effects of inappropriate
treatment in this patient population, continuing educa-
tion and training addressing the correct diagnosis of
BD and rational use of psychotropic medications are
needed in China.
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